It has been reported that Google's AI research division,
Google DeepMind , and BioNTech , the biotechnology company that developed the new coronavirus vaccine with Pfizer, are each working on developing an AI assistant specialized for scientific research.
The artificial intelligence program AlphaFold 3, rolled out by Google DeepMind and Isomorphic Labs earlier this month, has been called “groundbreaking,” holding transformative potential in drug discovery.
The hype is warranted, said Patrick Bangert, senior vice president of data, analytics, and AI at Searce, a cloud services company.
The latest version of Google DeepMind and Isomorphic Labs’ AlphaFold model can predict the structure and relationships not only of proteins, but “all of life’s molecules”, according to its developers.
French startup Bioptimus emerged from stealth following a seed funding round of $35M. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model technologies that capture the various scales of biology.
At the start of a biennial contest to predict the structure of proteins, the expectations for Google’s artificial intelligence unit DeepMind couldn’t have been higher. Think Mike Tyson in the mid-1980s: Everyone was expecting a knockout.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Researches from Google’s DeepMind, UCL and Moorfields Eye Hospital have used Artificial Intelligence to build software that can identify dozens of eye diseases from 3D scans and can recommend patients for appropriate treatment.
Artificial Intelligence can predict acute kidney injury (AKI) 48 hours before it happens, according to new research.
Google’s DeepMind can predict this leading cause of patient harm, according to latest research published in the journal Nature.
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
In eye care, artificial intelligence systems have shown they can match the accuracy of doctors in diagnosing specific diseases. But a new system designed by Google DeepMind and British doctors goes a crucial step further: It can show users how it reached its conclusions.